公开(公告)号：US20170368038A1

公开(公告)日：2017-12-28

申请号：US15534324

申请日：2015-12-08

Applicant: Novartis AG

Inventor： Michael Badman ,  LIoyd B. Klickstein ,  Bryan Laffitte

IPC: A61K31/439 ,  A61K31/497 ,  A61K31/426 ,  A61K31/506 ,  A61K31/422

CPC classification number: A61K31/439 ,  A61K31/422 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/506

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.

公开(公告)号：US20220347190A1

公开(公告)日：2022-11-03

申请号：US17760893

申请日：2020-09-18

Applicant: Novartis AG

Inventor： Michael Badman ,  Clifford Brass ,  Bryan Laffitte ,  Iwona KSIAZEK

IPC: A61K31/575 ,  A61K31/46 ,  A61K31/4162 ,  A61K45/06

Abstract: The invention provides, FXR agonists for the treatment of a condition mediated by Farnesoid X receptor (FXR), in particular liver disease or intestinal disease, in a subject in need thereof, to reduce drug-induced adverse side effects inpatients suffering from such diseases or conditions.

公开(公告)号：US20210361638A1

公开(公告)日：2021-11-25

申请号：US16767078

申请日：2018-11-28

Applicant: NOVARTIS AG

Inventor： Michael Badman ,  Clifford Brass ,  Bryan Laffitte

IPC: A61K31/46 ,  A61K47/54 ,  A61P1/16

Abstract: The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 μg to about 250 μg, to a subject in need thereof.

公开(公告)号：US20200276178A1

公开(公告)日：2020-09-03

申请号：US16645704

申请日：2018-09-11

Applicant: NOVARTIS AG

Inventor： Michael Badman ,  Clifford Brass ,  Bryan Laffitte

IPC: A61K31/46 ,  A61K31/197 ,  A61K31/192 ,  A61K31/4162 ,  A61P1/16

Abstract: The invention provides pharmaceutical compositions comprising a farnesoid X receptor (FXR) agonist or caspase inhibitor and another therapeutic agent, e.g.. PPAR-delta agonist in particular for treating or preventing liver diseases or disorders.

公开(公告)号：US20190083473A1

公开(公告)日：2019-03-21

申请号：US16137360

申请日：2018-09-20

Applicant: Novartis AG

Inventor： Michael Badman ,  Lloyd B. Klickstein ,  Bryan Laffitte

IPC: A61K31/439 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/426 ,  A61K31/422 ,  A61K31/506

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.

公开(公告)号：US11344540B2

公开(公告)日：2022-05-31

申请号：US16078409

申请日：2017-02-20

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/12 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61K47/54 ,  A61P1/16 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.

公开(公告)号：US11229634B2

公开(公告)日：2022-01-25

申请号：US16078403

申请日：2017-02-17

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/12 ,  A61K31/497 ,  A61K31/506 ,  A61K31/4748 ,  A61K47/54 ,  A61P1/00 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.

公开(公告)号：US11110083B2

公开(公告)日：2021-09-07

申请号：US16078431

申请日：2017-02-20

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/16 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.

公开(公告)号：US11052069B2

公开(公告)日：2021-07-06

申请号：US16333030

申请日：2017-09-12

Applicant: NOVARTIS AG

Inventor： Bryan Laffitte ,  Andreas Bauer ,  Michael Badman ,  Jin Chen ,  Patrick Mueller ,  Rachel Soon

IPC: A61K31/4162 ,  A61K31/4178 ,  A61P1/16 ,  A61K9/00 ,  A61K31/55 ,  A61K45/06

Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.

公开(公告)号：US20190161483A1

公开(公告)日：2019-05-30

申请号：US16202637

申请日：2018-11-28

Applicant: Novartis AG

Inventor： Michael Badman ,  Clifford Brass ,  Bryan Laffitte

IPC: C07D451/02 ,  A61P1/16

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific doses of tropifexor, in particular for treating or preventing liver diseases.